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OBJECTIVE—The pathophysiological mechanisms to explain
the association between risk of type 2 diabetes and elevated con-
centrations of g-glutamyltransferase (GGT) and alanineamino-
transferase (ALT) remain poorly characterized. We explored the
association of liver enzymes with peripheral and hepatic insulin
resistance, insulin secretion, insulin clearance, and glucagon
concentration.
RESEARCH DESIGN AND METHODS—We studied 1,309
nondiabetic individuals from the Relationship between Insulin
Sensitivity and Cardiovascular disease (RISC) study; all had
a euglycemic-hyperinsulinemic clamp and an oral glucose toler-
ance test (OGTT) with assessment of insulin secretion and
hepatic insulin extraction. The hepatic insulin resistance index
was calculated in 393 individuals.
RESULTS—In both men and women, plasma concentrations of
GGT and ALT were inversely related with insulin sensitivity (M/I)
(all P , 0.01). Likewise, the hepatic insulin resistance index was
positively correlated with both GGT (r = 0.37, P , 0.0001, men;
r = 0.36, P , 0.0001, women) and ALT (r = 0.25, P = 0.0005, men;
r = 0.18, P = 0.01, women). These associations persisted in mul-
tivariable models. Increased GGT and ALT were signiﬁcantly as-
sociated with higher insulin secretion rates and with both reduced
endogenous clearance of insulin and hepatic insulin extraction
during the OGTT (P = 0.0005 in men; P = 0.003 in women). Plasma
fasting glucagon levels increased over ALT quartiles (men, quartile
4 vs. quartile 1 11.2 6 5.1 vs. 9.3 6 3.8 pmol/L, respectively, P =
0.0002; women, 9.0 6 4.3 vs. 7.6 6 3.1, P =0 . 0 0 1 ) .
CONCLUSIONS—In healthy individuals, increased GGT and
ALT were biomarkers of both systemic and hepatic insulin
resistance with concomitant increased insulin secretion and
decreased hepatic insulin clearance. The novel ﬁnding of a
positive correlation between ALT and fasting glucagon level
concentrations warrants conﬁrmation in type 2 diabetes. Diabetes
60:1660–1667, 2011
M
arkers of liver function, speciﬁcally g-gluta-
myltransferase (GGT) and alanine amino-
transferase (ALT), predict incident type 2
diabetes in various populations (1–5). This
has been conﬁrmed by a recent meta-analysis that sug-
gested that GGT may be a better diabetes predictor than
ALT (6). We recently reported that a moderate elevation of
GGT concentration within the normal range is a strong risk
marker for incident type 2 diabetes in a large nonobese
population, independently of the homeostasis model as-
sessment index (7). However, the physiopathological
mechanisms that underlie the association between GGT,
ALT, and the risk of diabetes remain poorly understood.
Studies have shown that elevated levels of ALT reﬂect
peripheral insulin resistance (8,9), but speciﬁca s s e s s -
ment of hepatic insulin sensitivity with appropriate methods
is lacking. Furthermore, the relationship between ele-
vated liver markers, including GGT, and both insulin
secretion and insulin clearance has not previously been
addressed.
The aim of the current study is to determine whether liver
markers (GGT and ALT) are mainly associated with periph-
eral insulin resistance (assessed by the hyperinsulinemic-
euglycemic clamp), hepatic insulin resistance (assessed
through endogenous glucose production), or insulin se-
cretion (assessed during the oral glucose tolerance test
[ O G T T ] )i nal a r g ec o h o r to fh e a l t h ym e na n dw o m e n
participating in the Relationship between Insulin Sensi-
tivity and Cardiovascular disease (RISC) study (10,11). We
performed a sex-speciﬁc analysis because both GGT and
ALT values are classically higher in men compared with
women.
RESEARCH DESIGN AND METHODS
RISC is a prospective observational cohort study whose rationale and meth-
odology have been published, as well as the characteristics of the individuals
recruited (10,11). Clinically healthy men and women, aged 30–60 years, were
recruited from the local population of 19 centers in 14 European countries.
Initial exclusion criteria were as follows: treatment for obesity, hypertension,
lipid disorders or diabetes, pregnancy, cardiovascular or chronic lung disease,
weight change $5 kg in the last 6 months, cancer (in last 5 years), and renal
failure. Exclusion criteria after screening were as follows: arterial blood
pressure $140/90 mmHg, fasting plasma glucose $7.0 mmol/L, 2-h plasma
glucose (following a 75-g OGTT) $11.0 mmol/L, total serum cholesterol $7.8
mmol/L, serum triglycerides $4.6 mmol/L, and electrocardiogram abnormali-
ties. The present analysis is based on the 1,309 participants who satisﬁed all of
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ORIGINAL ARTICLEthe above criteria, whose clamp study passed the quality-control check, and
for whom liver markers were available.
Ethics committee approval was obtained by each recruiting center. Vol-
unteers were given detailed written information on the study and an oral ex-
planation, and they all signed a consent form.
Lifestyle and medical history. Information was collected on smoking and
physical activity. Alcohol intake was assessed using a standardized question-
naire and quantiﬁed in grams per week. Height, body weight, and BMI were
recorded and percent body fat and fat-free mass (FFM) were evaluated by the
TANITA bioimpedance balance (Tanita International Division). Obesity was
deﬁned as BMI $30 kg/m
2. Information on physical activity was collected with
the 7-day International Physical Activity Questionnaire (IPAQ), a previously
validated assessment tool for international studies that provides a compre-
hensive evaluation of daily physical activity habits (12).
OGTT. Blood samples were taken before and at 30, 60, 90, and 120 min into the
OGTT, together with samples for central analysis of routine blood chemistry.
Blood collected during the studies was separated into plasma and serum,
aliquoted, and stored at 220°C for glucose and at 280°C for lipids.
Glucose concentrations were measured by the glucose oxidase technique.
Plasma insulin and C-peptide were measured by a two-site time-resolved ﬂuoro-
immunoassay (AutoDELFIA Insulin kit; Wallac Oy, Turku, Finland) using
monoclonal antibodies, with the following assay characteristics (for insulin and
C-peptide, respectively): sensitivity 1–2 and 5 pmol/L, within-assay variation 5
and 5%, and between-assay variation 5 and 3.5%. Liver enzymes were centrally
assayed on a Dade-Behring Dimension RXL Autoanalyser in Cambridge, U.K.
Serum adiponectin was determined in Aarhus, Denmark, by an in-house time-
resolved immunoﬂuorometric assay (TR-IFMA) based on two antibodies and
recombinant human adiponectin, which measures total circulating adipo-
nectin (including high and low molecular–mass isoforms) (R&D Systems,
Abingdon, U.K.) (13). All standards and unknown samples were analyzed in
duplicate, with the exception of nonspeciﬁc binding, which was analyzed in
quadruplicate. The intraassay coefﬁcient of variation (CV) was ,5% and the
interassay CV was ,10%. Glucagon was assayed in Odense, Denmark, by the
glucose-oxidase method (Cobas Integra, Roche), which is highly speciﬁc for
the free C-terminus of the molecule and therefore speciﬁc for pancreatic
glucagon, with the following assay characteristics: normal range (5–20 pmol/L),
sensitivity ,1 pmol/L; within-assay CV ,5% at 20 pmol/L; and between-assay
CV ,12% (11).
Insulinclamp.Onaseparatedaywithin1monthoftheOGTT,a hyperinsulinemic-
euglycemic clamp was performed. Exogenous insulin was administered as
a primed-continuous infusion at a rate of 240 pmol/min per m
2 simultaneously
with a variable 20% dextrose infusion adjusted every 5–10 min to a maintain
plasma glucose level within 0.8 mmol/L (615%) of the target glucose level
(4.5–5.5 mmol/L). The clamp procedure was standardized across centers; the
data from each clamp study were immediately transferred to the coordinating
center where they underwent quality-control scrutiny according to preset
criteria.
In this cohort, a subset of 393 individuals had an assessment of fasting
endogenous glucose production (EGP) by a continuous infusion of 6,6-[
2H]
glucose for 2 h in basal before the beginning of the clamp. Plasma samples
were collected every 15 min, from 0 to 90 min, and every 5–10 min from 90 to
120 min for the determination of plasma glucose and insulin concentrations,
and glucose enrichment was measured by gas chromatography mass spec-
trometry. Basal EGP was calculated as the ratio between the tracer infusion
rate (micromoles per min per kilogram of FFM) and the tracer-to-tracee ratio.
The individuals who had an assessment of fasting endogenous glucose pro-
duction by the tracer infusion were slightly younger (43 6 8 vs. 44 6 8 years,
P = 0.02) and had a higher BMI and waist circumference (88 6 14 vs. 86 6 12
cm, P = 0.01) but did not differ for ALT or GGT activities compared with those
who did not have the EGP assessment. The hepatic insulin resistance index
was calculated as the product of fasting insulinemia and endogenous glucose
production (14,15).
Data analysis. Insulin sensitivity was expressed as the ratio of the M value
during the ﬁnal 40 min of the 2 h clamp to the mean plasma insulin concen-
tration measured during the same interval (M/I) and normalized to FFM and
expressed in units of mmol $ min
21 $ kg FFM
21 $ (nmol $ L
21)
21.
Insulin secretion was calculated during the OGTT by C-peptide deconvo-
lution (16). Total insulin secretion corresponds to the integral of insulin se-
cretion during the entire OGTT.
The endogeneous insulin clearance during the OGTT (in L/min per m
2)w a s
deﬁned as follows: (mean insulin secretion) / (mean insulin concentration),
where the means were calculated by trapezoids. Hepatic insulin fractional
extraction during the OGTT was determined as follows: 1 2 (clearance from
the clamp) / (endogenous clearance during the OGTT), where insulin clear-
ance from the clamp (in L/min per m
2) was calculated as the ratio between
insulin infusion and steady-state insulin concentration in the last 40 min of the
clamp.
Visit at year 3. As planned in the design of the cohort, at 3 years each par-
ticipant was invited for anOGTT; 575 women and 476men attended this second
OGTT following the same methods as described above. Participants who
attended this second visit were signiﬁcantly older than those who did not come
back, but there were no differences for waist, fasting glycemia, M/I, GGT, or
ALT values at baseline. Impaired fasting glucose was deﬁned as fasting glu-
cose $6.1 mmol/L, and impaired glucose tolerance was deﬁned as fasting
glucose ,7.0 mmol/L and 2-h glucose $7.8 mmol/L but ,11 mmol/L.
Statistical analysis. The data are expressed as means 6 SD or as median
(interquartile range) for variables with a skewed distribution, and categorical
data are expressed as percentages. Variables that were not normally distrib-
uted were log transformed before analyses. Data were analyzed for men and
women separately. The relationships between GGT, ALT, and either insulin
sensitivity or insulin secretion were assessed ﬁrst by linear regression analysis
with adjustment for age and recruitment center. Secondly, physical activity,
alcohol intake, and waist circumference were added into the regression
model. The relations between quartiles of both GGT and ALT activities and
each outcome of interest were tested by a multivariable linear regression
analysis, adjusting for age, recruitment center, physical activity, alcohol in-
take, and waist circumference. Logistic regression analysis was used to assess
the relationship between liver marker activities and the risk of impaired glu-
cose tolerance at year 3 after adjustment for the same covariates. Statistical
analyses used StatView for Windows (version 5.0; SAS Institute, Cary, NC) and
SAS (version 9.2; SAS Institute).
RESULTS
Both GGT and ALT values were signiﬁcantly higher in men
than in women (Table 1, P , 0.001 for both). Men had
a higher mean BMI than women at baseline.
Fasting and 2-h glycemia. In men, fasting glycemia was
more strongly correlated with GGT than ALT activity
(Table 2). In women, fasting glycemia was more tightly
associated with ALT than GGT activity (Table 2). In both
sexes, GGT was correlated with 2-h glycemia even after
taking into account possible confounding factors: age,
center, physical activity, alcohol intake, and waist cir-
cumference (P = 0.004 in women and P = 0.037 in men). In
contrast, ALT activity was no longer related with 2-h gly-
cemia in either men (P = 0.08) or women (P = 0.10) in
multivariable models after further adjustment for the
confounding factors cited above.
Insulin sensitivity. In both men and women, a higher
ALT or GGT activity was signiﬁcantly associated with
a lower M/I after adjustment for age and center (Table 2).
This association was unchanged in multivariable models.
Accordingly, insulin sensitivity decreased across quartiles
of both ALT and GGT after adjustment for age, center,
physical activity, alcohol intake, and waist circumference
(Table 3). Likewise, the hepatic insulin resistance index
was positively correlated with both ALT and GGT activity,
with a stronger correlation for GGT in both sexes (Table 2,
Fig. 1).
This association between GGT and both peripheral
and hepatic insulin resistance persisted after exclusion of
participants with GGT values above the normal range in
both sexes. The association between ALT and M/I was no
longer signiﬁcant for men when the analysis was restricted
to those with normal values but it persisted for women.
Insulin secretion. Basal and total insulin secretion rates
were signiﬁcantly associated with both liver markers
(Table 2). This association persisted after adjustment for
M/I. Insulin secretion increased across quartiles of GGT
after adjustment for age, center, physical activity, alcohol
intake, waist, and M/I (Table 3). A similar pattern was
observed for ALT in men but did not reach statistical
signiﬁcance in women (Table 4). These relationships be-
tween liver markers and insulin secretion persisted after
exclusion of participants with GGT or ALT values above
the normal range in both men and women.
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clearance of insulin and hepatic insulin extraction during
the OGTT were negatively associated with GGT activity
after adjustment for age and recruitment center (Table 2).
Both decreased across quartiles of GGT, in men and
women, in the multivariable model (Table 3). There was no
association between insulin clearance and ALT activity in
multivariable regression (Table 4).
Glucagon concentration. Fasting glucagon level was
signiﬁcantly correlated with ALT concentrations in both
men and women after adjustment for age, center, physical
activity, alcohol intake, and waist circumference (Table 2,
Fig. 2). The relationship between fasting glucagon and
GGT levels was weaker, and the association remained
signiﬁcant in the multivariable model in men only (Table 2).
In both men and women, the association between fasting
glucagon and ALT persisted after adding BMI and waist
circumference in the multivariable model (P =0 . 0 1i n
men and P = 0.003 in women). This association was in-
dependent of GGT activity, M/I, fasting glycemia, and
fasting insulinemia.
Impaired glucose tolerance after 3 years. ALT level
was not associated with fasting glycemia at year 3 in either
men or women. Baseline GGT was signiﬁcantly related to
fasting glycemia at year 3 in men only (b = 0.12, P = 0.009).
Baseline GGT but not ALT activities were signiﬁcantly
associated with 2-h glycemia at year 3 in both men (b =
0.12, P = 0.01) and women (b = 0.11, P = 0.02) in the
multivariable model. Sixty-one men and 78 women had 2-h
glucose $7.8 mmol/L at year 3. GGT $30 UI/L in men and
GGT $20 UI/L in women were, respectively, associated
with a signiﬁcantly increased risk of impaired glucose
TABLE 1
Characteristics of participants: the RISC study
Men Women
n 586 723
Age (years) 43 (8) 44 (8)
Current smoker 162 (28%) 179 (25%)
BMI (kg/m
2) 26.4 (3.5) 24.8 (4.3)
Physical activity (MET-min $ week
21) 2,212 (960–4,657) 2,133 (990–4,830)
Alcohol intake (g $ week
21) 74 (30–144) 30 (11–65)
Waist circumference (cm) 93 (10) 81 (12)
Fasting glucose (mmol $ L
21) 5.3 (0.8) 4.9 (0.6)
2-h Glycemia (mmol $ L
21) 5.7 (1.5) 5.8 (1.5)
Fasting insulin (pmol $ L
21) 37.0 (20.0) 33.7 (19.1)
Fasting glucagon (pmol $ L
21)1 0 ( 7 –12) 8 (6–9)
Adiponectin (mg $ L
21) 5.97 (4.62–7.77) 9.35 (7.17–12.18)
GGT (UI $ L
21) 26 (18–34) 17 (12–21)
ALT (UI $ L
21) 22 (16–28) 15 (11–18)
M/I (mmol $ min
21 $ kg FFM
21 $ [nmol $ L
21]
21) 111.4 (80.0–151.0) 144.6 (107.2–189.6)
Hepatic insulin resistance index (pmol $ L
21 $ mmol $ min
21 $ kg FFM
21)* 0.38 (0.26–0.55) 0.42 (0.28–0.62)
Basal insulin secretion rate (pmol/min per m
2) 74.2 (55.6–97.8) 66.8 (52.0–86.5)
Total insulin secretion rate during OGTT (nmol/m
2) 39.4 (31.5–49.6) 39.4 (32.2–48.4)
Endogenous clearance of insulin during OGTT (L/min per m
2) 1.57 (1.22–1.87) 1.63 (1.30–2.00)
Hepatic insulin extraction during OGTT (dimensionless) 0.61 (0.51–0.69) 0.62 (0.54–0.70)
Data are means (SD) or median (1st–3rd quartile) unless otherwise indicated. *Calculated in 393 individuals.
TABLE 2
Standardized b-coefﬁcients from linear regression between ALT and GGT activities and metabolic variables: the RISC study
ALT (IU $ L
21) GGT (IU $ L
21)
Men Women Men Women
b P b P b P b P
Fasting glycemia (mmol $ L
21) 0.08 0.046 0.22 ,0.0001 0.12 0.004 0.14 0.0001
2-h Glycemia (mmol $ L
21) 0.13 0.001 0.13 0.0004 0.13 0.002 0.10 0.005
Fasting glucagon (pmol $ L
21) 0.12 0.004 0.14 0.0002 0.09 0.03 0.06 0.09
Fasting insulinemia (pmol $ L
21) 0.33 ,0.0001 0.17 ,0.0001 0.24 ,0.0001 0.16 ,0.0001
M/I (mmol $ min
21 $ kg FFM
21 $ [nmol $ L
21]
21) 20.18 ,0.0001 20.15 ,0.0001 20.17 ,0.0001 20.11 ,0.0001
Hepatic insulin resistance index
(pmol $ L
21 mmol $ min
21 kg FFM
21)* 0.24 0.0003 0.16 0.029 0.28 ,0.0001 0.27 ,0.0001
Basal insulin secretion rate (pmol/min per m
2) 0.30 ,0.0001 0.18 ,0.0001 0.23 ,0.0001 0.17 ,0.0001
Total insulin secretion rate during OGTT (nmol/m
2) 0.23 ,0.0001 0.12 0.001 0.18 ,0.0001 0.18 ,0.0001
Endogenous clearance of insulin during OGTT
(L/min per m
2) 20.14 0.0007 20.07 0.05 20.16 0.0002 20.12 0.002
Hepatic insulin extraction during OGTT (dimensionless) 20.15 0.0005 20.06 0.09 20.14 0.0005 20.09 0.02
b-Coefﬁcients are adjusted for recruitment center and age. *Calculated in 393 individuals.
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4.91], P = 0.002; women, 2.03 [1.09–3.78], P = 0.024).
DISCUSSION
The main ﬁnding of this study is that GGT and ALT ac-
tivities were strongly associated with both peripheral and
hepatic insulin resistance and reduced hepatic insulin ex-
traction in healthy men and women. A moderate elevation
of both GGT and ALT activities within the normal range
appears to be a strong marker for insulin resistance, in-
dependently of abdominal adiposity or obesity. This is in
agreement with a large body of evidence showing a sig-
niﬁcant association between GGT and ALT activity and
incidence of type 2 diabetes in both sexes and in different
populations (1–4,7,8).
A previous report in Pima Indians showed that GGT and
ALT levels were inversely correlated with peripheral and
hepatic insulin sensitivity (17). In the Insulin Resistance
Atherosclerosis Study (IRAS) cohort, ALT levels were in-
versely associated with insulin sensitivity, as assessed by
the frequently sampled intravenous glucose tolerance test
(9); however, GGT levels were not reported and hepatic
insulin resistance was not assessed.
We expand these ﬁndings in a European cohort with
gold standard methods—the euglycemic-hyperinsulinemic
clamp with a tracer infusion—and we show that an ele-
vation in either GGT or ALT is associated with increased
systemic and liver insulin resistance in both men and
women. Of interest, the mean concentration of GGT in our
population was two times lower than that in the obese
Pima cohort, extending the relationship between liver
enzymes and insulin resistance to normal values. Another
report showed that in 75 nondiabetic men, GGT but not
ALT activities were inversely related to insulin sensitivity,
independently of intra-abdominal fat (18). The sample size
was smaller, and insulin sensitivity was assessed by in-
travenous glucose tolerance test rather than the clamp,
which may explain the lack of signiﬁcant correlation with
ALT activity.
The robustness of the association between both GGT
and ALT and M/I is substantiated by the fact that the re-
lationship persists in both men and women after exclusion
of participants with values above the normal range. A
subtle elevation of either liver enzyme could therefore be
viewed as an indirect marker of enhanced hepatic insulin
resistance and impaired glucose disposal in skeletal mus-
cles. The association between GGT and insulin resistance
is not related to the amount of visceral adipose tissue;
adjustment for waist circumference did not alter the re-
lationship. However, we cannot formally exclude the ab-
sence of substantial fatty liver in the participants because
an ultrasonography was not performed. A previous report
suggested that the relation between GGT and insulin sen-
sitivity is independent of intra-abdominal fat, as assessed
by tomodensitometry (18). Previous studies have shown
that diabetic hyperglycemia is related to increased hepatic
glucose production and the hepatic insulin resistance in-
dex is further increased in the presence of nonalcoholic
fatty liver disease (19). In the current study, we have
shown a correlation of the hepatic insulin resistance index
with ALT and GGT, further explaining the prognostic value
of these two variables on the risk of type 2 diabetes.
In our study, the positive association between liver
markers and insulin resistance appears to be independent
of alcohol intake and persisted after exclusion of heavy
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those with higher GGT or ALT concentration cannot be
related to increased alcohol consumption, given that al-
cohol intake was positively correlated with M/I in our
study (data not shown). Similarly, it has been shown that
nondrinkers with high GGT or ALT levels had a higher risk
of type 2 diabetes (20). A potential mechanism underlying
the association between GGT and insulin resistance may
be related to oxidative stress and the role of cellular GGT
in the metabolism of extracellular reduced glutathione. It
has been proposed that cellular GGT may be involved in
the production of reactive oxygen species in the presence
of iron or other transition metals (21). Therefore, serum
GGT might be considered a sensitive enzyme related to oxi-
dative stress, which is associated with insulin resistance (22).
Fasting glucagon concentration was signiﬁcantly asso-
ciated with ALT levels only. Fasting glucagon levels are
elevated in type 2 diabetic patients and are related to basal
hepatic glucose production and fasting glycemia (14,23).
To our knowledge, the relationship between liver enzymes
and glucagon concentration has not previously been in-
vestigated. Our ﬁndings on a positive correlation between
ALT and fasting glucagon levels suggest a putative new
mechanism to explain why elevated ALT is predictive of
the development of type 2 diabetes (17,24,25). Fasting
plasma glucagon level has been shown to be independently
associated with whole-body insulin resistance (26). There
was a similar trend for GGT to increase across elevated
glucagon levels, but the relation appears to be stronger for
ALT than for GGT. Plasma ALT is considered to be a more
speciﬁc marker of hepatocyte alterations than GGT. This
positive association of glucagon and ALT appeared to be
independent of both fasting glycemia and insulinemia, sug-
gesting a speciﬁc yet poorly characterized interaction
between the liver and a-cell function. Reciprocally, a possi-
ble direct effect of glucagon on ALT secretion in the liver
cannot be excluded and deserves further experimental
investigations. Experiments in dogs have shown that glu-
cagon chronically impairs hepatic tissue glucose uptake
(27). In addition, glucagon increases CYP2E1 mRNA levels
in cultured hepatocytes, suggesting a possible pathway by
which the glucagon may directly affect the hepatocyte (28).
This novel ﬁnding of a positive correlation between ALT
activity and fasting glucagon concentrations suggests the
potential interest of ALT in clinical practice to identify
individuals with fasting elevated glucagon secretion, war-
ranting conﬁrmation in type 2 diabetes.
The current study showed that an increase in GGT
concentration was associated with diminished hepatic
extraction of insulin. This aspect has not previously been
FIG. 1. Hepatic insulin resistance index for men (left panel) and women (right panel) according to quartiles of both ALT and GGT. Bars show
means 6 SEM. P value is adjusted for age, center, physical activity, alcohol intake, and waist circumference after a logarithmic transformation.
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across GGT quartiles may be related to concomitant in-
creased insulin resistance and, consequently, elevated in-
sulin concentrations. Previous studies have underscored
an inverse relationship among basal insulin resistance,
insulin secretion during a glucose load, and insulin clear-
ance (29–33). During insulin resistance, glucose homeo-
stasis is maintained by an increase in plasma insulin via
increased secretion or decreased hepatic insulin extrac-
tion. Animal studies indicate that after induction of obesity-
mediated insulin resistance, an initial increase in insulin
secretion is followed by a decrease in ﬁrst-pass hepatic in-
sulin extraction (34). The reduction of hepatic insulin ex-
traction with increasing levels of insulin secretion is also
explained by a saturation of the insulin receptor on
hepatocytes (35). The elevation in GGT activity could be a
biological consequence of a chronic high ﬂux of portal ve-
nous insulin with increased receptor-mediated insulin en-
docytosis in the liver.
Besides insulin resistance, we observed a positive and
signiﬁcant correlation between GGT and ALT activities
and insulin secretion rates. Increased basal insulin secre-
tion during the OGTT in the participants with higher GGT
or ALT levels could be viewed as a direct consequence of
enhanced hepatic and systemic hepatic insulin resistance.
However, the observation that adjustment for insulin sen-
sitivity did not alter the strong and positive association
between liver enzymes and insulin secretion suggests al-
ternative mechanisms such as a possible interaction be-
tween the liver and the endocrine pancreas.
Moderate elevations in liver enzymes do not appear to
be related to a concomitantly diminished acute insulin
response to glucose. Therefore, our ﬁndings underscore
that the association between liver enzymes and the in-
creased risk of type 2 diabetes observed in a number of
epidemiological studies does not directly rely on im-
paired insulin secretion. However, our cross-sectional
data do not preclude the possibility of a subsequent de-
cline in b-cell function over time in those with elevated
liver enzymes.
Limitations of the current study include the absence of
serial measures of b-cell function over time. Alcohol con-
sumption is difﬁcult to evaluate because of possible un-
derreporting and misclassiﬁcation. However, the results
were not altered after exclusion of heavy drinkers. The
strengths of the current study are the large RISC cohort of
healthy subjects, the use of the gold standard methodology
for measurement of insulin sensitivity with centralized
laboratory assays and assessment of insulin secretion, and
continuous quality control of data (10). This provided the
opportunity to systematically explore, for both men and
women, the relationship between liver enzymes and pe-
ripheral and hepatic insulin sensitivity, insulin secretion,
insulin clearance, and glucagon concentration.
In conclusion, our study shows that in healthy men and
women, increased GGT and ALT activities within their
physiological ranges are associated with peripheral but
also hepatic insulin resistance, increased insulin secretion,
and decreased hepatic insulin clearance. Furthermore,
ALT activities were positively associated with fasting glu-
cagon concentrations, independently of insulinemia, waist
circumference, or insulin sensitivity. These ﬁndings con-
ﬁrm the role of the liver in the pathogenesis of type 2 di-
abetes. The novel ﬁnding of a positive correlation between
ALT and fasting glucagon concentrations needs to be
conﬁrmed in type 2 diabetes.
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APPENDIX
RISC recruiting centers and investigators. Amsterdam,
the Netherlands: R.J. Heine, J. Dekker, S. de Rooij, G. Nijpels,
and W. Boorsma; Athens, Greece: A. Mitrakou, S. Tournis,
K. Kyriakopoulou, and P. Thomakos; Belgrade, Serbia: N. Lalic,
K .L a l i c ,A .J o t i c ,L .L u k i c ,a n dM .C i v c i c ;D u b l i n ,I r e l a n d :
J. Nolan, T.P. Yeow, M. Murphy, C. DeLong, G. Neary, M.P.
Colgan, and M. Hatunic; Frankfurt, Germany: T. Konrad,
H. Böhles, S. Fuellert, F. Ber, and H. Zuchhold; Geneva,
Switzerland: A. Golay, E. Harsch Bobbioni, V. Barthassat,
V. Makoundou, T.N.O. Lehmann, and T. Merminod; Glasgow,
Scotland: J.R. Petrie (now at D u n d e e ) ,C. P e r r y ,F .N e a r y ,
C. MacDougall, K. Shields, and L. Malcolm; Kuopio, Finland:
M .L a a k s o ,U .S a l m e n n i e m i ,A .A u r a ,R .R a i s a n e n ,U .
Ruotsalainen, T. Sistonen, M. Laitinen, and H. Saloranta;
London, U.K.: S.W. Coppack, N. McIntosh, J. Ross, L.
Pettersson, and P. Khadobaksh; Lyon, France: M. Laville,
F. Bonnet (now at Rennes), A. Brac de la Perriere, C.
Louche-Pelissier, C. Maitrepierre, J. Peyrat, S. Beltran, and
A. Serusclat; Madrid, Spain: R. Gabriel, E.M. Sánchez,
R. Carraro, A. Friera, and B. Novella; Malmö, Sweden (1):
P. Nilsson, M. Persson, and G. Östling; Malmö, Sweden (2):
O. Melander and P. Burri; Milan, Italy: P.M. Piatti, L.D. Monti,
E. Setola, E. Galluccio, F. Minicucci, and A. Colleluori;
Newcastle-upon-Tyne, U.K.: M. Walker, I.M. Ibrahim, M.
Jayapaul, D. Carman, C. Ryan, K. Short, Y. McGrady, and
D. Richardson; Odense, Denmark: H. Beck-Nielsen, P. Stehr,
K. Hojlund, V .Vestergaard, C. Olsen, and L. Hansen; Perugia,
Italy: G.B. Bolli, F. Porcellati, C. Fanelli, P. Lucidi, F. Calcinaro,
and A. Saturni; Pisa, Italy: E. Ferrannini, A. Natali, E. Muscelli,
S. Pinnola, M. Kozakova, A. Casolaro, and B.D. Astiarraga;
Rome, Italy: G. Mingrone, C. Guidone, A. Favuzzi, and
P. Di Rocco; Vienna, Austria: C. Anderwald, M. Bischof,
M. Promintzer, M. Krebs, M. Mandl, A. Hofer, A. Luger,
W. Waldhäusl, and M. Roden.
Project management board. B. Balkau (Villejuif, France),
S.W. Coppack (London, U.K.), J.M. Dekker (Amsterdam, the
Netherlands), E. Ferrannini (Pisa, Italy), A. Golay (Geneva,
FIG. 2. Fasting glucagon concentration for men (top panel) and women (bottom panel) according to quartiles of ALT. Bars show means 6 SEM.
P value is adjusted for age, center, physical activity, alcohol intake, and waist circumference after a logarithmic transformation.
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1666 DIABETES, VOL. 60, JUNE 2011 diabetes.diabetesjournals.orgSwitzerland), A. Mari (Padova, Italy), A. Natali (Pisa, Italy), J.
Petrie (Dundee, Scotland), and M. Walker (Newcastle, U.K.).
Core laboratories and reading centers. Lipids (Dublin,
Ireland): P. Gaffney, J. Nolan, and G. Boran; hormones
(Odense, Denmark): C. Olsen, L. Hansen, and H. Beck-
Nielsen; albumin:creatinine (Amsterdam, the Netherlands):
A. Kok and J. Dekker; genetics (Newcastle-upon-Tyne,
U.K.): S. Patel and M. Walker; stable isotope laboratory
(Pisa, Italy): A. Gastaldelli and D. Ciociaro; adiponectin,
C-reactive protein, and mannose-binding lectin (Odense,
Denmark): A. Flyvbjerg; ultrasound reading centre (Pisa,
Italy): M. Kozakova; electrocardiogram reading (Villejuif,
France): M.T. Guillanneuf; actigraph (Villejuif, France):
B. Balkau and L. Mhamdi; data management (Villejuif,
France, and Padova and Pisa, Italy): B. Balkau, A. Mari,
L. Mhamdi, L. Landucci, S. Hills, and L. Mota; mathematical
modeling and Web site management (Padova, Italy): A. Mari,
G. Pacini, C. Cavaggion and A. Tura; and the coordinating
ofﬁce (Pisa, Italy): S.A. Hills, L. Landucci, and L. Mota.
Further information on the RISC study and participating
centers can be found at www.egir.org.
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